Clinical Activity of Elraglusib with Gemcitabine Plus Nab-paclitaxel in First-Line Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma By Ogkologos - April 27, 2026 207 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the phase II study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Remembering With Gratitude January 7, 2021 Patient Guide on Immunotherapy Side Effects and Their Management Now Available... November 26, 2025 EMA Recommends Extension of Indications for Tislelizumab to First-Line Treatment of... November 19, 2024 T-DM1 Approval Expanded to Include Some Women with Early-Stage HER2-Positive Breast... May 23, 2019 Load more HOT NEWS Financial Navigation Can Reduce the Financial Toxicity of Cancer Care FDA Amends Indication for Pembrolizumab in the First-Line Treatment for Patients... Let’s talk about HPV: 6 common questions answered T-DM1 is Active and Well Tolerated in Patients with HER2-positive Metastatic...
